Hairy Cell Leukemia-Case Study
INDEX
1. CONSENT FORM (SEE ATTACHED) 2. CASE PERSENTATION 3.1 DIAGNOSIS 3.2 CASE HISTORY/SIGNS AND SYMPTOMS 3.3 RISK FACTORS –DEVELOPING 3.4 FACTORS THAT REDUCE THE RISK 3.5 SCREENING FOR HCL 3.6 DIAGNOSTIC TESTS 3.7 DIFFERENCE –SCREENING/DIAGNOSTIC 3. TREATMENT 4.8 STAGES OF HCL 4.9 GOAL 4.10 TREATMENT PLAN OF CASE-HCL 4.11 ONCOLOGY EMERGENCIES -HCL
(i)
CASE STUDY CONSENT FORM
Case Study Name: B-Tech Oncology: Medical Surgical Nursing IV Assignment 1 Hospital: Little Company Of Mary Hospital, Pretoria Oncology Unit: Mary Potter Oncology Unit Ward A Principle Investigator: MJM (Tienie) Ackermann – Oncology Student
-------------------------------------------------
Note: This consent form is to be retained by the investigator and kept secure. At the completion of the case study, it should be disposed of in a secure fashion.
-------------------------------------------------
Student may be asked by the Tutor to provide this form as proof that consent has been obtained.
Thank you for your continuous participation ! I will be the principle investigator for your case study. Should you have any questions, please do not hesitate to contact me. My cell phone number is 0722194568.
Risks: Although no type of care – medical or alternative – is 100% safe and without risks, the care you receive from your oncologist is safe and proven effective. Your oncologist would be more than happy to discuss this further with you.
Benefits: You will not receive any payment for your participation in this study. However, the information collected from your participation in this study may help your oncologist and other clinicians provide a safer and future treatment for you and other patients.
Confidentiality: Identification of you is strictly prohibited. The case study is completely anonymous. No reference will ever be made in oral or written reports that could link you to
1. CONSENT FORM (SEE ATTACHED) 2. CASE PERSENTATION 3.1 DIAGNOSIS 3.2 CASE HISTORY/SIGNS AND SYMPTOMS 3.3 RISK FACTORS –DEVELOPING 3.4 FACTORS THAT REDUCE THE RISK 3.5 SCREENING FOR HCL 3.6 DIAGNOSTIC TESTS 3.7 DIFFERENCE –SCREENING/DIAGNOSTIC 3. TREATMENT 4.8 STAGES OF HCL 4.9 GOAL 4.10 TREATMENT PLAN OF CASE-HCL 4.11 ONCOLOGY EMERGENCIES -HCL
(i)
CASE STUDY CONSENT FORM
Case Study Name: B-Tech Oncology: Medical Surgical Nursing IV Assignment 1 Hospital: Little Company Of Mary Hospital, Pretoria Oncology Unit: Mary Potter Oncology Unit Ward A Principle Investigator: MJM (Tienie) Ackermann – Oncology Student
-------------------------------------------------
Note: This consent form is to be retained by the investigator and kept secure. At the completion of the case study, it should be disposed of in a secure fashion.
-------------------------------------------------
Student may be asked by the Tutor to provide this form as proof that consent has been obtained.
Thank you for your continuous participation ! I will be the principle investigator for your case study. Should you have any questions, please do not hesitate to contact me. My cell phone number is 0722194568.
Risks: Although no type of care – medical or alternative – is 100% safe and without risks, the care you receive from your oncologist is safe and proven effective. Your oncologist would be more than happy to discuss this further with you.
Benefits: You will not receive any payment for your participation in this study. However, the information collected from your participation in this study may help your oncologist and other clinicians provide a safer and future treatment for you and other patients.
Confidentiality: Identification of you is strictly prohibited. The case study is completely anonymous. No reference will ever be made in oral or written reports that could link you to